Research progress of ovarian cancer apoptosis related factor—Survivin and Smac

doi:10.3760/cma.j.issn.1673-422X.2015.04.020

Abstract

Abstract: Survivin is the strongest member of the inhibitor of apoptosis protein (IAP) family. Smac is the second mitochondriaderived activator of cysteine proteases, which can promote apoptosis by combining with IAP. Abnormal expression of them is closely related with occurrence, development, treatment tolerance and prognosis of ovarian cancer. It is prompted that Survivin and Smac are expected to play important roles in the early diagnosis and targeted therapy of ovarian cancer.

Key words: Ovarian neoplasms, Cell apoptosis, Survivin, Smac

MA Dan-；Ma-Ling. Research progress of ovarian cancer apoptosis related factor—Survivin and Smac[J]. Journal of International Oncology, 2015, 42(4): 313-315.

References

［1］ Zhang LQ, Wang J, Jiang F, et al. Prognostic value of survivin in patients with nonsmall cell lung carcinoma:a systematic review with metaanalysis［J］. PLoS One, 2012, 7(3): e34100. ［2］ Végran F, Boidot R, Bonnetain F, et al. Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma［J］. Endocr Relat Cancer, 2011, 18(6): 783792. ［3］ GasowskaBodnar A, Bondnar L, Dabek A, et al. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadujuvant chemotherapy［J］. Int J Gynecol Cancer, 2014, 24(4): 687696. ［4］ McKenzie JA, Grossman D. Role of the apoptotic andmitotic regulator survivin in melanoma［J］. Anticancer Res, 2012, 32(2): 397404. ［5］ Cai X, Ma S, Gu M, et al. Survivin regulates the expression of VEGFC in lymphatic metastasis of breast cancer［J］. Diagn Pathol, 2012, 7: 52. ［6］ Sun H, Liu L, Lu J, et al. Cyclopeptide Smac mimetics as antagonists of IAP proteins［J］. Bioorg Med Chem Lett, 2010, 20(10): 30433046. ［7］王智勇, 张雪培, 魏金星, 等. Smac和XIAP基因在肾细胞癌中的表达及意义［J］. 中国实用医刊, 2010, 37(17): 45. ［8］ Qiu W, Liu H, Sebastini A, et al. An apoptosisindependent role of SMAC in tumor suppression［J］. Oncogene, 2013, 32(19): 23802389. ［9］ Edison N, Zuri D, Maniv I, et al. The IAPantagonist ARTS initiates caspase activation upstream of cytochrome C and SMAC/Diablo［J］. Cell Death Differ, 2012, 19(2): 356368. ［10］刘莉霞, 李术平, 何秀萍. Survivin蛋白在卵巢癌组织中的表达及临床意义［J］. 黑龙江医药科学, 2014, 37(2): 2931. ［11］ Wang HX, Chen G, Li GL, et al. Expression and significance of Survivin and Smac in ovarian mucinous tumors［J］. Zhonghua Bing Li Xue Za Zhi, 2010, 39(6): 387390. ［12］钱雪雅, 席晓薇, 李林霞, 等. Survivin 细胞核表达与上皮性卵巢癌预后的关系［J］. 现代生物医学进展, 2010, 10(10): 18201824. ［13］ Xing J, Jia CR, Wang Y, et al. Effect of shRNA targeting survivin on ovarian cancer［J］. J Cancer Res Clin Oncol, 2012, 138 (7): 12211229. ［14］王艳伟, 李维山, 张延新, 等. Smac/Diablo 和 actived caspase3 在卵巢浆液性肿瘤中的表达［J］. 中外医疗, 2011, 30 (8): 90. ［15］黄晓春, 代维栋. Survivin与Smac在卵巢上皮性肿瘤中的表达及其相关性研究［J］. 延安大学学报(医学科学版), 2011, 9(1): 46. ［16］ Petrucci E, Pasquini L, Bernabei M, et al. A small molecule SMAC mimic LBW242 potentiates TRAIL and anticancer drugmediated cell death of ovarian cancer cells［J］. PLoS One, 2012, 7(4): e35073. ［17］王术国, 管洪在, 扈新花, 等. 慢性粒细胞白血病Smac和Survivin基因表达及意义［J］. 青岛大学医学院学报, 2008, 44(1): 5153. ［18］ Mansour A, Nabil M, AliLabib R, et al. Reciprocal expression of Survivin and Smac/Dlablo in primary breast cancer［J］. Med Oncol, 2012, 29(4): 25352542.

[1]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[2]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui. Research progress of Nrf2 in ovarian cancer [J]. Journal of International Oncology, 2023, 50(8): 493-497.
[3]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[4]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[5]	Li Chenxi, Zhao Hongwei. Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors [J]. Journal of International Oncology, 2021, 48(3): 180-183.
[6]	Li Zhefeng, Li Jie, Zhao Xiaoting, Yue Wentao. GLDC regulates proliferation and apoptosis of ovarian cancer cells through PI3K/Akt/mTOR pathway [J]. Journal of International Oncology, 2021, 48(12): 716-722.
[7]	Zheng Jing, Yao Sheng, Shen Wenjie, Sun Zhijia, Zhao Hui, Fu Yan, Gao Ke, Du Nan. Clinical study of intraperitoneal infusion of bevacizumab combined with albumin paclitaxel and carboplatin in carcinomatous peritoneal adhesion from ovarian cancer [J]. Journal of International Oncology, 2021, 48(11): 660-665.
[8]	Wei Mengyu, Ma Li. Research advances of Mfn2 in tumor [J]. Journal of International Oncology, 2021, 48(1): 45-47.
[9]	Yang Lifen, Song Wei, Xu Dawei, Wu Jun, Gao Ran. Mechanisms of miR-103a-3p/CHI3L1 in proliferation and vascular mimicry of ovarian cancer cells [J]. Journal of International Oncology, 2020, 47(6): 333-339.
[10]	Xue Chen, Zhao Yue, Shi Guang, Tang Yan. Research progress of PD-1/PD-L1 inhibitors in ovarian cancer [J]. Journal of International Oncology, 2020, 47(5): 312-315.
[11]	Wang Ying, Yang Wei, Xiao Juxiang. Expressions of SIRT6 and survivin in gastric cancer tissue and their clinical significances [J]. Journal of International Oncology, 2020, 47(4): 217-222.
[12]	Yang Yiting, Cheng Zhongping. The role of inflammatory cytokines in chemoresistance of epithelial ovarian cancer [J]. Journal of International Oncology, 2020, 47(4): 249-251.
[13]	Fan Yangyang, Wang Ying, Yuan Feng, Du Shanping, He Rongrong, Jia Yan. Study on the mechanism of MALAT1 targeting miR-142-3p in ovarian cancer chemotherapy resistance [J]. Journal of International Oncology, 2020, 47(2): 82-89.
[14]	Xu Liben, Wu Chaoyang, Wang Yuandong. Study on the effect of docosahexaenoic acid combined with cisplatin on the growth of human gastric cancer xenografts in nude mice and its mechanism [J]. Journal of International Oncology, 2020, 47(11): 656-662.
[15]	Quan Ruiquan, Zhang Li, Kuang Li, Li Hongbo, Xiao Meixian. Efficacy of olaparib combined with bevacizumab in the treatment of patients with recurrent platinum-sensitive ovarian cancer and its effect on serum HE4, CA125 and CTC levels [J]. Journal of International Oncology, 2020, 47(10): 606-610.